Table 2.
Estimates of the mean areas under the curve of the intravenous and intranasal formulations and mean bioavailability of the intranasal formulation from noncompartmental analysis for midazolam and 1-hydroxymidazolam. Values are mean±s.d.
| Parameter | Midazolam | 1-Hydroxymidazolam |
|---|---|---|
| AUCi.v. (mg l−1 min) | 13.0±4.7 | 1.76±0.61 |
| AUCi.n. (mg l−1 min) | 10.2±3.3 | 1.27±0.43 |
| FAUC | 0.80±0.19 | 0.79±0.41 |